BOSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) — Carrick Therapeutics Inc., an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced positive results from the Phase 2 SUMIT-BC clinical trial evaluating samuraciclib in combination with fulvestrant in patients with second-line advanced hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer who were previously treated with a CDK4/6 inhibitor therapy. The clinical trial results were presented today in a late-breaking poster presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS). Samuraciclib is an oral first-in-class CDK7 inhibitor (CDK7i).
